Related Experiment Video
Updated: Apr 19, 2026
08:18
Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
Published on: July 27, 2022
1.7K
Do we need 'new' omega-3 polyunsaturated fatty acids formulations?
Arrigo F G Cicero1, Martino Morbini, Claudio Borghi
1Alma Mater Studiorum University of Bologna, Medical and Surgical Sciences Department , Bologna , Italy.
Expert Opinion on Pharmacotherapy
|December 5, 2014
Summary
Omega-3 fatty acids (PUFAs) show therapeutic potential, but efficacy varies due to product quality and bioavailability. Research into new sources and forms is crucial for optimizing benefits in cardiovascular disease and beyond.
Area of Science:
- Nutritional Science
- Biochemistry
- Pharmacology
Background:
- Omega-3 polyunsaturated fatty acids (PUFAs), primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from fish oil, are widely studied for therapeutic benefits, especially in cardiovascular disease.
- Observed variations in PUFA efficacy across conditions and dosages are partly attributed to differences in product quality and bioavailability.
Discussion:
- Investigating novel sources like Krill oil and new pharmaceutical forms, such as omega-3 carboxylic acids, is essential.
- The goal is to identify formulations with superior bioavailability and efficacy while reducing production costs.
Key Insights:
- Product quality and bioavailability significantly impact the therapeutic efficacy of omega-3 PUFAs.
- Further research is needed to optimize omega-3 PUFA delivery and effectiveness.
Outlook:
- Future research should explore long-term PUFA supplementation to enhance existing evidence-based therapies for cardiovascular disease prevention.
- Understanding PUFA's role in managing other conditions with potential benefits is also a key area for future investigation.
Related Concept Videos
03:38Structure of Lipids
102.5K
Lipids include a diverse group of compounds that are largely nonpolar in nature. This is because they are hydrocarbons that include mostly nonpolar carbon-carbon or carbon-hydrogen bonds. Non-polar molecules are hydrophobic (“water fearing”), or insoluble in water. Lipids perform many different functions in a cell. Cells store energy for long-term use in the form of fats. Lipids also provide insulation from the environment for plants and animals. For example, they help keep aquatic...
102.5K
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
227
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
227
01:27Bioavailability Enhancement: Drug Permeability Enhancement
321
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
321
01:11Oral Drug Delivery Systems: Delayed-Release Systems
187
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
187
01:19Modified-Release Drug Delivery Systems: Overview
212
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
212
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K